Test Price
2,800 AEDโ Home Collection Available
XRCC3 Melanoma Susceptibility (Familial Cutaneous Malignant Melanoma Type 6) Genetic Test in UAE
Executive Summary & Core Metrics
Core Clinical Metrics & Service Framework
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Telephonic post-test genetic counselling for result interpretation.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
This next-generation sequencing (NGS) analysis of the XRCC3 gene identifies germline mutations associated with familial cutaneous malignant melanoma type 6, enabling early risk stratification and personalised prevention planning. The test is processed in a DHA-licensed, ISO-accredited laboratory facility located in Dubai Healthcare City.
Test Overview & Methodology
The XRCC3 NGS test provides comprehensive coverage of the XRCC3 gene, detecting single nucleotide variants, small insertions and deletions, and splice-site alterations down to 1% variant allele frequency. This methodology significantly outperforms legacy Sanger sequencing in sensitivity and breadth of detection, particularly for mosaic or low-level mutations.
| Feature | Our XRCC3 NGS Test (UAE) | Closest Alternative (Legacy Sanger Sequencing) |
|---|---|---|
| Precision | Full gene coverage, detection of rare variants down to 1% variant allele frequency | Limited to known hotspot regions, lower sensitivity for mosaic mutations |
| Methodology | Next Generation Sequencing (NGS) โ DHA/MOHAP standardized panel | Sanger sequencing (single amplicon) |
| Turnaround Time | 21 to 28 business days (GCC cold-chain logistics) | 14 to 21 business days (limited gene regions) |
Physician Insight & Safety Protocols
โAs a consultant medical genetics specialist regulated by the Dubai Health Authority, I confirm that the XRCC3 NGS test serves as a risk-stratification tool rather than a standalone diagnostic assay. A positive result indicates elevated lifetime susceptibility to cutaneous melanoma, warranting intensified dermatologic surveillance, UV avoidance counselling, and cascade screening of first-degree relatives. A negative result does not eliminate all residual risk. I am committed to guiding each patient through personalised pre-test and post-test genetic counselling to ensure informed decision-making and appropriate clinical follow-up.โ โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not alter or discontinue any prescribed medication regimen without prior consultation with your treating physician. This genetic test does not replace ongoing pharmacologic management.
Exclusion Criteria & Emergency Red Flags
- Inability to provide informed consent โ minors must comply with Federal Decree-Law No. 4 of 2016 on Medical Liability and have legal guardian approval.
- Acute febrile illness or systemic infection requiring immediate medical care.
- Emergency symptoms: rapidly growing skin lesion, bleeding or ulcerated mole, unexplained weight loss โ these require urgent in-person dermatologic evaluation, not genetic testing alone.
- Known allergy to antiseptics used in venipuncture โ discuss alternative sampling methods with your clinician.
Patient FAQ & Clinical Guidance
1. What does a positive XRCC3 mutation mean for my melanoma risk?
A pathogenic XRCC3 variant elevates your lifetime risk for cutaneous melanoma, mandating intensive surveillance and formal genetic counselling. This germline alteration is associated with familial melanoma type 6 and increases the probability of developing malignant melanoma. Recommended management includes total-body photography, dermatoscopy at six-month intervals, strict UV protection, and avoidance of tanning beds. First-degree relatives should be offered cascade genetic testing.
2. How is the XRCC3 NGS test performed in the UAE?
NGS testing on a home-collected blood sample typically yields results within three to four weeks. A certified phlebotomist visits your home or office between 8 AM and 11 PM to collect a peripheral whole blood specimen in a DNA-stabilising tube. The sample is transported under validated temperature-controlled cold-chain to our ISO-accredited laboratory in Dubai Healthcare City. You receive a secure electronic report interpreted by a consultant medical geneticist.
3. Is genetic counselling mandatory before and after the test?
Yes, pre-test and post-test genetic counselling is strongly recommended and integral to the responsible clinical use of XRCC3 testing. UAE regulatory standards under Federal Decree-Law No. 4 of 2016 on Medical Liability and international best practice require a dedicated counselling session to document a three-generation family pedigree, explain the autosomal inheritance pattern, and discuss potential medicolegal implications. Our service includes a session with a DHA-licensed genetic counsellor; results are disclosed exclusively during the post-test consultation to ensure emotional support and accurate interpretation within the full clinical context.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
This test is conducted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient genetic data is encrypted, access-controlled, and processed exclusively within secure UAE infrastructure. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
DNA Labs UAE holds DHA Facility License Number 1143 and operates under the regulatory oversight of the Dubai Health Authority. All laboratory processes conform to ISO 9001:2015 quality management standards (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | XRCC3 Melanoma Susceptibility (Familial Cutaneous Malignant Melanoma Type 6) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 21 to 28 Business Days |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Next Generation Sequencing (NGS) โ Full Gene Coverage |
| ICD-10-CM Code | Z15.09 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | DHA Facility License: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians